Advertisement
1. To approve the appointment of Kost, Forer, Gabbay & Kasierer (a memberof Ernst & Young Global), as the Company's independent registered publicaccounting firm for the fiscal year ending December 31, 2007 and its serviceas the Company's independent registered public accounting firm until the nextAnnual General Meeting and to authorize the Board of Directors of theCompany, upon recommendation of the Audit Committee, to fix remuneration ofsaid firm; and
Advertisement
2. To report on the business of the Company for the year ended December31, 2006 (including a review of the 2006 audited consolidated financialstatements).
The affirmative vote of the holders of a majority of the voting powerrepresented at the meeting in person or by proxy, and voting thereon, isnecessary for the approval of the first proposal.
Shareholders of record at the close of business on August 31, 2007, areentitled to notice of, and to vote at, the Annual Meeting. All shareholdersare cordially invited to attend the Annual Meeting in person.
A proxy statement describing the matter to be voted upon at the meetingwith a proxy card enabling the Shareholders to indicate their vote on suchmatter will be mailed on or around September 2, 2007 to all Shareholdersentitled to vote at the Annual Meeting and is also available on the Company'swebsite at www.rosettagenomics.com and on the SEC's website at www.sec.gov.
Shareholders who do not expect to attend the Meeting in person arerequested to mark, date, sign and mail the proxy card to the office of theCompany's transfer agent, American Stock Transfer & Trust Company located at6201 15th Ave, Brooklyn, NY 11219, not less than twenty four (24) hoursbefore the time fixed for the Annual Meeting in order to be qualified toparticipate in meeting.
About Rosetta Genomics
Rosetta Genomics (Nasdaq: ROSG) is a leader in the development ofmicroRNA-based diagnostics and therapeutics. Founded in 2000, the company'sintegrative research platform combining bioinformatics and state-of-the-artlaboratory processes has led to the discovery of hundreds of biologicallyvalidated novel human microRNAs. Building on its strong IP position andstrategic alliances with leading biotechnology companies, Rosetta Genomics isworking to develop a full range of diagnostic and therapeutic products basedon microRNAs. The company's primary focus is in the development ofmicroRNA-based products to diagnose and treat different forms of cancer andinfectious diseases.Contact: Media Alan Zachary T: +1-(312)-944-6784 [email protected] Investors Juliane Snowden T: +1-(212)-213-0006 [email protected]
SOURCE Rosetta Genomics Ltd
